The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease
Authors:
- 29 February 2012
- journal article
- research article
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 27 (12) , 1248-1257
Abstract
Objective: The use of psychotropic medications in Alzheimer's disease (AD) has been associated with both deleterious and potentially beneficial outcomes. We examined the longitudinal association of psychotropic medication use with cognitive, functional, and neuropsychiatric symptom (NPS) trajectories among community‐ascertained incident AD cases from the Cache County Dementia Progression Study.Methods: A total of 230 participants were followed for a mean of 3.7 years. Persistency index (PI) was calculated for all antidepressants, selective serotonin reuptake inhibitors (SSRIs), antipsychotics (atypical and typical), and benzodiazepines as the proportion of observed time of medication exposure. Mixed‐effects models were used to examine the association between PI for each medication class and Mini‐Mental State Exam (MMSE), Clinical Dementia Rating Sum of Boxes (CDR‐Sum), and Neuropsychiatric Inventory – Total (NPI‐Total) trajectories, controlling for appropriate demographic and clinical covariates.Results: At baseline, psychotropic medication use was associated with greater severity of dementia and poorer medical status. Higher PI for all medication classes was associated with a more rapid decline in MMSE. For antidepressant, SSRI, benzodiazepine, and typical antipsychotic use, a higher PI was associated with a more rapid increase in CDR‐Sum. For SSRIs, antipsychotics, and typical antipsychotics, a higher PI was associated with more rapid increase in NPI‐Total.Conclusions: Psychotropic medication use was associated with more rapid cognitive and functional decline in AD, and not with improved NPS. Clinicians may tend to prescribe psychotropic medications to AD patients at risk of poorer outcomes, but one cannot rule out the possibility of poorer outcomes being caused by psychotropic medications. Copyright © 2012 John Wiley & Sons, Ltd.Keywords
This publication has 41 references indexed in Scilit:
- Progression of Cognitive, Functional, and Neuropsychiatric Symptom Domains in a Population Cohort With Alzheimer Dementia: The Cache County Dementia Progression StudyThe American Journal of Geriatric Psychiatry, 2011
- Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS-2)?International Journal of Geriatric Psychiatry, 2011
- Sertraline for the Treatment of Depression in Alzheimer Disease: Week-24 OutcomesThe American Journal of Geriatric Psychiatry, 2010
- Sertraline for the Treatment of Depression in Alzheimer DiseaseThe American Journal of Geriatric Psychiatry, 2010
- Clinical Symptom Responses to Atypical Antipsychotic Medications in Alzheimer’s Disease: Phase 1 Outcomes From the CATIE-AD Effectiveness TrialAmerican Journal of Psychiatry, 2008
- Point and 5‐year period prevalence of neuropsychiatric symptoms in dementia: the Cache County StudyInternational Journal of Geriatric Psychiatry, 2007
- Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD miceExperimental Neurology, 2007
- Antipsychotics and cognitive decline in Alzheimer's disease: the LASER-Alzheimer's disease longitudinal studyJournal of Neurology, Neurosurgery & Psychiatry, 2007
- The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deteriorationJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984